Dimerix Limited (DXB.AX)
- Previous Close
0.4800 - Open
0.7500 - Bid 0.6800 x --
- Ask 0.6000 x --
- Day's Range
0.6550 - 0.7600 - 52 Week Range
0.3000 - 0.7600 - Volume
39,987,280 - Avg. Volume
2,191,878 - Market Cap (intraday)
380.433M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Jul 21, 2025 - Jul 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 24, 1999
- 1y Target Est
0.84
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
dimerix.comRecent News: DXB.AX
View More
Performance Overview: DXB.AX
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXB.AX
View MoreValuation Measures
Market Cap
380.43M
Enterprise Value
359.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
53.07
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-79.26%
Return on Equity (ttm)
-524.69%
Revenue (ttm)
737.87k
Net Income Avi to Common (ttm)
-23.31M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
21.11M
Total Debt/Equity (mrq)
2.18%
Levered Free Cash Flow (ttm)
-10.23M